Wai Yuen Tong Medicine Holdings Limited provided earnings guidance for the financial year ended 31 March 2023. For the period, the company expected to record a loss attributable to owners of the parent of not more than HKD 35 million for the financial year ended 31 March 2023 as compared with a loss attributable to owners of the parent for the financial year ended 31 March 2022 of approximately HKD 108.9 million as published in the Company's 2022 annual report.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.229 HKD | +0.44% | 0.00% | -42.75% |
1st Jan change | Capi. | |
---|---|---|
-42.75% | 32.98M | |
+45.15% | 6.34B | |
-14.00% | 4.61B | |
+9.54% | 3.39B | |
-8.99% | 3.29B | |
+50.03% | 2.02B | |
-6.97% | 1.73B | |
-0.31% | 1.67B | |
+50.00% | 1.63B | |
-10.61% | 1.59B |
- Stock Market
- Equities
- 897 Stock
- News Wai Yuen Tong Medicine Holdings Limited
- Wai Yuen Tong Medicine Holdings Limited Provides Earnings Guidance for the Financial Year Ended 31 March 2023